Nasdaq · CIK 0001781174
ACRV Acrivon Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 5 d ago. Close $1.91 on Oct 9, 2026, +48% from the 52-week low and -37% from the high.
Last 90 days
Net insider value
-$585
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$585 by 1 insider
Insiders on file
17
with a Form 4 at this company
Price and insider trades, last year
ACRVOct 9, 2026 · close 1.91
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Acrivon Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Mary Miller Chief Legal Officer sell | $585 294 shares | -0% | - | |
| 42Moderate | Perceptive Advisors LLC owner sell | $1.0M 736,767 shares | -19% | - | |
| 47Moderate | Perceptive Advisors LLC owner sell | $2.7M 1,519,952 shares | -28% | - |
Transactions
The last 57 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Mary Miller Chief Legal Officer | SOpen-market sale Common Stock | -294 | $1.99 | $585 | 81,715 | 5 d ago |
| Aug 31, 2026 | Michaela Levin Chief Business Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 30,000 | 40 d ago |
| Aug 31, 2026 | Michaela Levin Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +130,000 | $0.00 | $0 | 130,000 | 40 d ago |
| Jun 13, 2025 | Charles M Baum director | AGrant or award Stock Option (Right to Buy)derivative | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 13, 2025 | Ivana Magovcevic-Liebisch director | AGrant or award Stock Option (Right to Buy)derivative | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 13, 2025 | Santhosh Palani director | AGrant or award Stock Option (Right to Buy)derivative | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 13, 2025 | Sharon Shacham director | AGrant or award Stock Option (Right to Buy)derivative | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 13, 2025 | Michael John Tomsicek director | AGrant or award Stock Option (Right to Buy)derivative | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 13, 2025 | Derek DiRocco director | AGrant or award Stock Option (Right to Buy)derivative | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 13, 2025 | Ra Capital Management, L.p. director, owner | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnotes | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| May 21, 2025 | Peter Blume-Jensen President and CEO | FTax withholding Common Stock | -19,904 | $1.15 | $23k | 2,206,111 | May 23, 2025 |
| May 14, 2025 | Mary Miller Chief Legal Officer | FTax withholding Common Stock | -184 | $1.14 | $210 | 36,323 | May 16, 2025 |
| May 14, 2025 | Katharine Peterson Chief Accounting Officer | FTax withholding Common Stock | -99 | $1.14 | $113 | 4,320 | May 16, 2025 |
| May 14, 2025 | Erick Gamelin Chief Development Officer | FTax withholding Common Stock | -403 | $1.14 | $459 | 16,089 | May 16, 2025 |
| May 14, 2025 | Eric Devroe Chief Operating Officer | FTax withholding Common Stock | -613 | $1.14 | $699 | 66,534 | May 16, 2025 |
| May 14, 2025 | Peter Blume-Jensen President and CEO | FTax withholding Common Stock | -59,766 | $1.14 | $68k | 2,226,015 | May 16, 2025 |
| May 14, 2025 | Peter Blume-Jensen President and CEO | FTax withholding Common Stockindirect: See Footnote | -491 | $1.14 | $560 | 315,686 | May 16, 2025 |
| Apr 30, 2025 | Perceptive Advisors LLC owner | SOpen-market sale Common Stockindirect: See Footnote | -437,881 | $1.41 | $617k | 3,403,025 | May 1, 2025 |
| May 1, 2025 | Perceptive Advisors LLC owner | SOpen-market sale Common Stockindirect: See Footnote | -298,886 | $1.34 | $401k | 3,104,139 | May 1, 2025 |
| Apr 25, 2025 | Perceptive Advisors LLC owner | SOpen-market sale Common Stockindirect: See Footnote | -1,054,669 | $1.95 | $2.1M | 4,306,189 | Apr 29, 2025 |
| Apr 28, 2025 | Perceptive Advisors LLC owner | SOpen-market sale Common Stockindirect: See Footnote | -215,283 | $1.56 | $336k | 4,090,906 | Apr 29, 2025 |
| Apr 29, 2025 | Perceptive Advisors LLC owner | SOpen-market sale Common Stockindirect: See Footnote | -250,000 | $1.41 | $353k | 3,840,906 | Apr 29, 2025 |
| Apr 17, 2025 | Mary Miller Chief Legal Officer | FTax withholding Common Stock | -558 | $1.81 | $1,010 | 36,507 | Apr 18, 2025 |
| Apr 1, 2025 | Adam D. Levy Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +35,209 | $0.00 | $0 | 35,209 | Apr 3, 2025 |
| Apr 1, 2025 | Mary Miller Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +15,616 | $0.00 | $0 | 15,616 | Apr 3, 2025 |
| Mar 1, 2025 | Katharine Peterson Chief Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +31,900 | $0.00 | $0 | 31,900 | Mar 4, 2025 |
| Mar 1, 2025 | Mary Miller Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +93,693 | $0.00 | $0 | 93,693 | Mar 4, 2025 |
| Mar 1, 2025 | Rasmus Holm-Jorgensen Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +109,309 | $0.00 | $0 | 109,309 | Mar 4, 2025 |
| Mar 1, 2025 | Eric Devroe Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +140,540 | $0.00 | $0 | 140,540 | Mar 4, 2025 |
| Mar 1, 2025 | Jean-Marie Cuillerot Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +78,078 | $0.00 | $0 | 78,078 | Mar 4, 2025 |
| Mar 1, 2025 | Peter Blume-Jensen President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +390,390 | $0.00 | $0 | 390,390 | Mar 4, 2025 |
| Mar 1, 2025 | Erick Gamelin Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +78,078 | $0.00 | $0 | 78,078 | Mar 4, 2025 |
| Mar 1, 2025 | Peter Blume-Jensen President and CEO | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +140,540 | $0.00 | $0 | 140,540 | Mar 4, 2025 |
| Feb 21, 2025 | Peter Blume-Jensen President and CEO | FTax withholding Common Stock | -19,904 | $5.54 | $110k | 2,285,781 | Feb 25, 2025 |
| Feb 14, 2025 | Rasmus Holm-Jorgensen Chief Financial Officer | FTax withholding Common Stock | -434 | $5.42 | $2,352 | 26,088 | Feb 19, 2025 |
| Feb 14, 2025 | Katharine Peterson Chief Accounting Officer | FTax withholding Common Stock | -116 | $5.42 | $629 | 4,419 | Feb 19, 2025 |
| Feb 14, 2025 | Mary Miller Chief Legal Officer | FTax withholding Common Stock | -217 | $5.42 | $1,176 | 37,065 | Feb 19, 2025 |
| Feb 14, 2025 | Erick Gamelin Chief Development Officer | FTax withholding Common Stock | -469 | $5.42 | $2,542 | 16,492 | Feb 19, 2025 |
| Feb 14, 2025 | Eric Devroe Chief Operating Officer | FTax withholding Common Stock | -724 | $5.42 | $3,924 | 67,147 | Feb 19, 2025 |
| Feb 14, 2025 | Peter Blume-Jensen President and CEO | FTax withholding Common Stock | -37,152 | $5.42 | $201k | 2,305,685 | Feb 19, 2025 |
| Feb 14, 2025 | Peter Blume-Jensen President and CEO | FTax withholding Common Stockindirect: See Footnote | -579 | $5.42 | $3,138 | 316,177 | Feb 19, 2025 |
| Jan 17, 2025 | Mary Miller Chief Legal Officer | FTax withholding Common Stock | -659 | $5.78 | $3,809 | 37,282 | Jan 22, 2025 |
| Mar 1, 2024 | Mary Miller Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +67,567 | $0.00 | $0 | 67,567 | Nov 27, 2024 |
| Mar 1, 2024 | Rasmus Holm-Jorgensen Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +90,090 | $0.00 | $0 | 90,090 | Nov 27, 2024 |
| Mar 1, 2024 | Erick Gamelin Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +45,045 | $0.00 | $0 | 45,045 | Nov 27, 2024 |
| Mar 1, 2024 | Eric Devroe Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +90,090 | $0.00 | $0 | 90,090 | Nov 27, 2024 |
| Mar 1, 2024 | Peter Blume-Jensen President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +225,226 | $0.00 | $0 | 225,226 | Nov 27, 2024 |
| Mar 1, 2024 | Peter Blume-Jensen President and CEO | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +90,090 | $0.00 | $0 | 90,090 | Nov 27, 2024 |
| Nov 21, 2024 | Peter Blume-Jensen President and CEO | FTax withholding Common Stock | -19,910 | $6.44 | $128k | 2,342,837 | Nov 25, 2024 |
| Nov 14, 2024 | Rasmus Holm-Jorgensen Chief Financial Officer | FTax withholding Common Stock | -368 | $7.92 | $2,915 | 26,522 | Nov 18, 2024 |
| Nov 14, 2024 | Mary Miller Chief Legal Officer | FTax withholding Common Stock | -184 | $7.92 | $1,457 | 37,941 | Nov 18, 2024 |
| Nov 14, 2024 | Katharine Peterson Chief Accounting Officer | FTax withholding Common Stock | -99 | $7.92 | $784 | 4,535 | Nov 18, 2024 |
| Nov 14, 2024 | Erick Gamelin Chief Development Officer | FTax withholding Common Stock | -402 | $7.92 | $3,184 | 16,961 | Nov 18, 2024 |
| Nov 14, 2024 | Eric Devroe Chief Operating Officer | FTax withholding Common Stock | -613 | $7.92 | $4,855 | 67,871 | Nov 18, 2024 |
| Nov 14, 2024 | Peter Blume-Jensen President and CEO | FTax withholding Common Stock | -59,766 | $7.92 | $473k | 2,362,747 | Nov 18, 2024 |
| Nov 14, 2024 | Peter Blume-Jensen President and CEO | FTax withholding Common Stockindirect: See Footnote | -490 | $7.92 | $3,881 | 316,756 | Nov 18, 2024 |
| Oct 17, 2024 | Mary Miller Chief Legal Officer | FTax withholding Common Stock | -558 | $7.87 | $4,391 | 38,125 | Oct 21, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Charles M Baumdirector
- Peter Blume-JensenPresident and CEO
- Jean-Marie CuillerotChief Medical Officer
- Eric DevroeChief Operating Officer
- Derek DiRoccodirector
- Erick GamelinChief Development Officer
- Rasmus Holm-JorgensenChief Financial Officer
- Michaela LevinChief Business Officer
- Adam D. LevyChief Financial Officer
- Ivana Magovcevic-Liebischceo, president, officer, director
- Mary MillerChief Legal Officer
- Perceptive Advisors LLCdirector, owner
- Santhosh Palanidirector
- Katharine PetersonChief Accounting Officer
- Ra Capital Management, L.p.owner, director
- Sharon Shachamdirector
- Michael John Tomsicekdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.